terminator

By Targets:	Antibiotic (1) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) CMV (1) DNA/RNA Synthesis (6) Endogenous Metabolite (3) FKBP (1) HCV (1) HIV (4) HSV (1) Integrin (2) Isotope-Labeled Compounds (1) Nucleoside Antimetabolite/Analog (4) Orthopoxvirus (1) PKA (1) Potassium Channel (1) Reverse Transcriptase (4) Ser/Thr Protease (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (1) Infection (8) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Alkynes (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138561

EFdA-TP	Reverse Transcriptase DNA/RNA Synthesis HIV	Infection
EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms .

HY-138561A

EFdA-TP tetraammonium	Reverse Transcriptase DNA/RNA Synthesis HIV	Infection
EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms . EFdA-TP (tetraammonium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138561B

EFdA-TP tetrasodium	Reverse Transcriptase DNA/RNA Synthesis HIV	Infection
EFdA-TP tetrasodium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetrasodium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetrasodium inhibits HIV-1 RT with multiple mechanisms . EFdA-TP (tetrasodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3920

Cys-Kemptide

PKA Cancer

Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .
HY-P6009

Cys-αvβ6-BP

Integrin Cancer

Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .
HY-P6009A

Cys-αvβ6-BP TFA

Integrin Cancer

Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

Cys-Kemptide	PKA	Cancer
Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .

Cys-αvβ6-BP	Integrin	Cancer
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .

Cys-αvβ6-BP TFA	Integrin	Cancer
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

HY-W091784

3'-O-Methylguanosine	Endogenous Metabolite Orthopoxvirus Nucleoside Antimetabolite/Analog	Infection
3'-O-Methylguanosine is a methylated nucleoside analogs and a RNA chain terminator. 3'-O-methylguanosine can inhibit early virus-specific RNA synthesis .

HY-10240

Mericitabine Maximum Cited Publications 7 Publications Verification RG 7128; R-7128; PSI 6130 diisobutyrate	HCV	Infection
Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

HY-123523

Enocitabine	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CMV	Infection Cancer
Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities .

HY-P3150

Recombinant Proteinase K	Ser/Thr Protease	Others
Recombinant Proteinase K is a serine protease that cleaves the carboxy-terminated peptide bonds of aliphatic and aromatic amino acids. Recombinant Proteinase K can be used to digest proteins and remove contamination from nucleic acid preparations .

HY-14182

Vernakalant RSD1235	Potassium Channel	Cardiovascular Disease
Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

HY-W014282

4-Cumylphenol	Biochemical Assay Reagents	Others
4-Cumylphenol is a polycarbonate chain terminator. 4-Cumylphenol is widely used as a material for polycarbonate plastics, surfactants, fungicides and preservatives. 4-Cumylphenol also induces lipid accumulation in mouse adipocytes .

HY-138587

7-TFA-ap-7-Deaza-ddG	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Others
7-TFA-ap-7-Deaza-ddG (compound 19d, US20060281100A1), a nucleotide derivative, can be used in the synthesis of thiotriphosphate nucleotide dye terminators which can be used in DNA sequencing reactions .

HY-138588

7-TFA-ap-7-Deaza-ddA	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Others
7-TFA-ap-7-Deaza-ddA (compound 19c, US20060281100A1), a nucleotide derivative, can be used in the synthesis of thiotriphosphate nucleotide dye terminators which can be used in DNA sequencing reactions .

HY-17422B

Acyclovir monophosphate	HSV Antibiotic	Infection Cancer
Acyclovir monophosphate is a potent anti-herpes simplex virus (HSV) agent. Acyclovir monophosphate blocks DNA synthesis through the inhibition of the viral DNA polymerase and terminates the chain elongation of the viral DNA. Acyclovir monophosphate shows antitumor activity .

HY-126316

Zapalog 1 Publications Verification	FKBP	Others
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .

HY-Y0378

D-Leucine (R)-Leucine
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-138561C

EFdA-TP tetralithium	HIV Reverse Transcriptase	Infection
EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetralithium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetralithium inhibits HIV-1 RT with multiple mechanisms .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-137412

PGF2α 1,15-lactone Prostaglandin F2α 1,15-lactone	Others	Endocrinology
PGF2α 1,15-lactone (Prostaglandin F2α 1,15-lactone) is a lipid-soluble internal ester of PGF2α. PGF2α 1,15-lactone decreases menstrual cycle lengths in non-pregnant rhesus monkeys. PGF2α 1,15-lactone terminates early pregnancy in the monkey .

HY-P2860

Acetylcholinesterase, Fly head ACHE; EC 3.1.1.7	Cholinesterase (ChE)	Neurological Disease
Acetylcholinesterase, Fly head (ACHE; EC 3.1.1.7) is a cholinergic enzyme mainly found in neuromuscular junctions and cholinergic type chemical synapses used in biochemical research. Acetylcholinesterase, Fly head catalyzes the breakdown or hydrolysis of acetylcholine and some other choline esters that act as neurotransmitters into acetate and choline. Acetylcholinesterase, Fly head's main role is to terminate neuronal transmission and signaling between synapses to prevent ACh spread and activation of nearby receptors .

HY-E70053

alpha-1,3-Galactosyltransferase (GTB) alpha 1,3GT	Endogenous Metabolite	Metabolic Disease
alpha-1,3-Galactosyltransferase (GTB) (alpha 1,3GT) catalyzes the synthesis of the xenoantigen or α-galactose (α-Gal) epitope. alpha-1,3-Galactosyltransferase (GTB) transfers galactose from UDP-Gal to type 1 or type 2, αFuc1→2βGal-R (H)-terminating acceptors .

Cat. No.	Product Name

HY-L026

Clinical Compound Library	2219 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2219 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.

Clinical Compound Library

2219 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.

MCE owns a unique collection of 2219 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.

HY-L026P

Clinical Compound Library Plus	2714 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2714 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Clinical Compound Library Plus

2714 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.

MCE owns a unique collection of 2714 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Cat. No.	Product Name	Type

HY-E70053

alpha-1,3-Galactosyltransferase (GTB) alpha 1,3GT	Biochemical Assay Reagents
alpha-1,3-Galactosyltransferase (GTB) (alpha 1,3GT) catalyzes the synthesis of the xenoantigen or α-galactose (α-Gal) epitope. alpha-1,3-Galactosyltransferase (GTB) transfers galactose from UDP-Gal to type 1 or type 2, αFuc1→2βGal-R (H)-terminating acceptors .

Cat. No.	Product Name	Target	Research Area

HY-P4632

H-γ-Glu-Leu-OH

Peptides Others

H-γ-Glu-Leu-OH is a dipeptide consisting of γ-glutamic acid and leucine, terminated by a hydroxyl group .
HY-P3920

Cys-Kemptide

PKA Cancer

Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .
HY-P6009

Cys-αvβ6-BP

Integrin Cancer

Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .
HY-P6009A

Cys-αvβ6-BP TFA

Integrin Cancer

Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

H-γ-Glu-Leu-OH	Peptides	Others
H-γ-Glu-Leu-OH is a dipeptide consisting of γ-glutamic acid and leucine, terminated by a hydroxyl group .

Cys-Kemptide	PKA	Cancer
Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .

Cys-αvβ6-BP	Integrin	Cancer
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .

Cys-αvβ6-BP TFA	Integrin	Cancer
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W091784

3'-O-Methylguanosine	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Orthopoxvirus Nucleoside Antimetabolite/Analog
3'-O-Methylguanosine is a methylated nucleoside analogs and a RNA chain terminator. 3'-O-methylguanosine can inhibit early virus-specific RNA synthesis .

Cat. No.	Product Name	Chemical Structure

HY-Y0378S

D-Leucine-d10
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

Cat. No.	Product Name		Classification

HY-138561

EFdA-TP		Alkynes
EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms .

HY-138561A

EFdA-TP tetraammonium		Alkynes
EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms . EFdA-TP (tetraammonium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138561B

EFdA-TP tetrasodium		Alkynes
EFdA-TP tetrasodium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetrasodium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetrasodium inhibits HIV-1 RT with multiple mechanisms . EFdA-TP (tetrasodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry